Reports suggest that among those who could only breathe with the help of a ventilator, dexamethasone reduced deaths by one third, and by one-fifth in other patients receiving oxygen only.
As per the non-exclusive licensing agreement, Gilead will grant the Hyderabad-based drug maker the right to register and manufacture its investigational drug Remdesivir in 127 countries, Dr Reddy's Laboratories said in a statement.
One study, the article authors note, found that almost a quarter of COVID-19 patients - 24 per cent -- were suffering acute heart failure when they were first diagnosed with the coronavirus.
Under this licensing deal, Hetero will be supplying Remdesivir in 127 countries, including India, subject to regulatory approvals in respective countries.
Cipla is the second firm after Noida-based Jubilant Life Sciences whose subsidiary Jubilant Generics Ltdhas inked a pact with Gilead Sciences on Tuesday
The four drug regimes to be tested on patients are - Remdesivir, Lopinavir, Hydroxychloroquine or Chloroquine and Interferon.
The medication, recently given fast-track approval for use in the US, could be administered apart from clinical trials as early as Monday to the first coronavirus patients, while manufacturer Gilead is making plans to export it to other nations who give it the green light
In an FDA fact sheet for patients and their families and caregivers, the agency on Friday noted that remdesivir has not undergone the same type of review as an FDA-approved or cleared product, reports Xinhua news agency.
Major scientific institutions and startups of Hyderabad launched multiple initiatives solely aimed at checking the proliferation of Coronavirus and also play their part in the exit strategy of the ongoing lockdown
"Cell entry is the first step of cross-species transmission. SARS-CoV-2 is more likely to infect lung type II alveolar cells, which may explain the severe alveolar damage after infection," the scientists wrote in the research.